- Home
- FLC vs ADAP Comparison
FLC vs ADAP Comparison
Compare FLC & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- ADAP
- Stock Information
- Founded
- FLC 2003
- ADAP 2008
- Country
- FLC United States
- ADAP United Kingdom
- Employees
- FLC N/A
- ADAP N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- FLC Finance
- ADAP Health Care
- Exchange
- FLC Nasdaq
- ADAP Nasdaq
- Market Cap
- FLC 174.2M
- ADAP 75.5M
- IPO Year
- FLC N/A
- ADAP 2015
- Fundamental
- Price
- FLC $16.31
- ADAP $0.25
- Analyst Decision
- FLC
- ADAP Buy
- Analyst Count
- FLC 0
- ADAP 6
- Target Price
- FLC N/A
- ADAP $1.35
- AVG Volume (30 Days)
- FLC 37.8K
- ADAP 681.5K
- Earning Date
- FLC 01-01-0001
- ADAP 08-11-2025
- Dividend Yield
- FLC 6.64%
- ADAP N/A
- EPS Growth
- FLC N/A
- ADAP N/A
- EPS
- FLC N/A
- ADAP N/A
- Revenue
- FLC N/A
- ADAP $179,639,000.00
- Revenue This Year
- FLC N/A
- ADAP N/A
- Revenue Next Year
- FLC N/A
- ADAP $35.48
- P/E Ratio
- FLC N/A
- ADAP N/A
- Revenue Growth
- FLC N/A
- ADAP 878.53
- 52 Week Low
- FLC $12.62
- ADAP $0.20
- 52 Week High
- FLC $15.45
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- FLC 67.52
- ADAP 45.94
- Support Level
- FLC $16.86
- ADAP $0.23
- Resistance Level
- FLC $16.90
- ADAP $0.25
- Average True Range (ATR)
- FLC 0.13
- ADAP 0.02
- MACD
- FLC 0.01
- ADAP -0.00
- Stochastic Oscillator
- FLC 92.68
- ADAP 54.55
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.